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Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-
resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV)
antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.
Methods: A retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV
antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome
measures at the start and end of each IV course were recorded (FEV1%, FVC%).
Results: Twenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV:
39(20%)). FEV1% increased by 7.12(11.67)% after TIV (pb0.01) and 6.65(7.62)% after NTIV (pb0.01). There was no significant difference
between the IV courses in mean %change in lung function TIV versus NTIV (FEV1 0.46% [95%CI: −4.55 to 5.48%]).
Conclusion: These data suggest equivalence in the lung function outcome of IVantibiotic therapy includingtemocillin versus standard IVantibiotic
therapy.
© 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Temocillin; Burkholderia cepacia complex; Pseudomonas aeruginosa1. Introduction
Temocillin is a semi-synthetic 6-alpha-methoxy derivative of
ticarcillin which is highly stable to most bacterial beta-
lactamases [1–5]. The spectrum of temocillin is directed towards
aerobic Gram-negative bacteria but has no useful in-vitro
activity against anaerobes, Gram-positive bacteria and most☆ Previous poster presentations: Annual North American Cystic Fibrosis
Conference, November 2006, Denver, Colorado, European Cystic Fibrosis
Conference, June 2006, Copenhagen, Denmark.
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doi:10.1016/j.jcf.2008.06.005Gram-negative non-fermenters such as Pseudomonas aerugi-
nosa and Acinetobacter spp. [6]. This natural resistance of non-
fermenters has been attributed to an inability of the molecule to
enter the outer membrane of the cell wall [7–10]. Temocillin
does not disturb the gastrointestinal flora, it is non-toxic, and
well tolerated. Moreover antagonism against other antimicro-
bials is rare which may be due to the failure of temocillin to
induce beta-lactamase production [11–15]. Temocillin is
suitable for twice daily intravenous (IV) administration which
enhances acceptability and makes it a popular choice when
patients are given IV antibiotics at home [16].
Despite its spectrum temocillin has been used in cystic
fibrosis (CF) to treat exacerbations in severe lung disease,
particularly in patients infected with Burkholderia cepaciaropean Cystic Fibrosis Society.
Table 2
Baseline FEV1 and FVC of whole group and mean (SD) change during
temocillin and non-temocillin courses (values expressed as mean±SD)
Temocillin course Non-temocillin course
Baseline Increase Baseline Increase
FEV1% predicted 37 (18) 7.12 (11.67) 39 (20) 6.65 (7.62)
FVC% predicted 49 (22) 8.85 (14.04) 53 (23) 7.04 (7.96)
All difference between Temocillin and NON-Temocillin courses and non-
statistically significant (pN0.05).
552 L. Kent et al. / Journal of Cystic Fibrosis 7 (2008) 551–554complex and multi-resistant P. aeruginosa. Indeed, a syner-
gistic effect against P. aeruginosa has been shown in-vitro
when temocillin is used in combination with aminoglycoside
antibiotics, and temocillin has shown high in-vitro activity
against B. cepacia complex organisms, in comparison to other
beta-lactams [14,17,18]. Finally, clinical benefits of temocillin
have been reported in CF patients with B. cenocepacia
[16,19]. Although, the relationship between sensitivity of
isolates and clinical improvement is not clear [19,20]. Indeed,
in a study of CF patients concurrently infected with B. cepacia
complex and P. aeruginosa, temocillin was given in
combination with an IV aminoglycoside for acute exacerba-
tions of respiratory disease. Clinical improvement was
observed in nine out of twelve cases, two of which had pre-
treatment isolates which were resistant to temocillin, which
suggests that when in-vitro tests show resistance to temocillin
there can still be a clinical improvement [19].
2. Methods
2.1. Study design and population
A retrospective cross-over study of patients attending two
adult CF centres between 1997 and 2006 was performed.
Patients with B. cepacia complex or P. aeruginosa isolated
from sputum were included. Patients included had received a
course of antibiotics which included temocillin (TIV) and a
further course within ±1 year of the temocillin course which
did not include temocillin (NTIV). Courses were excluded if
the patient died during the course or if it was their final
course before death. Antibiotic prescribing had been based on
best physician choice and therefore was influenced by a number
of factors including previous antibiotic resistance patterns
and allergies/intolerances to other alternative antibiotics. Forced
expiratory volume in one second (FEV1) and forced vitalTable 1
Concomitant antibiotics for temocillin and non-temocillin courses
P. aeruginosa (n=10) B. cenocepacia (n=16)
Temocillin
course a
Non-temocillin
course
Temocillin
course a
Non-temocillin
course
Tobramycin
(n=9)
Tobramycin
(n=10)
Tobramycin
(n=12)
Tobramycin
(n=13)
Aztreonam
(n=3)
Meropenem (n=3) Meropenem
(n=6)
Meropenem (n=9)
Meropenem
(n=1)
Ceftazidime
(n=4)
Ceftazidime
(n=2)
Aztreonam (n=4)
Ceftazidime
(n=1)
Aztreonam (n=2) Chloramphenicol
(n=2)
Ceftazidime (n=4)
Ciproxin (n=1) Tazocin (n=1) Tazocin (n=2) Co-trimoxazole
(n=2)
Tazocin (n=1) Timentin (n=1) Amikacin (n=1) Chloramphenicol
(n=1)
Colomycin
(n=1)
Colistin (n=1) Tazocin (n=1)
Co-trimoxazole
(n=1)
Vibramycin (n=1)
a Antibiotics listed were administered in addition to temocillin.capacity (FVC) at the start and end of each antibiotic course
were recorded and expressed as a percentage of the predicted
value. The primary endpoint was change in spirometry
from baseline and used as a marker of the efficacy of the
antimicrobial treatment.
2.2. Statistical analysis
Mean and standard deviation were used to describe the
characteristics of the patients at baseline of each course.
Exploratory data analysis was used to assess the relationship
between the change in lung function and baseline lung function.
This analysis showed a relationship between baseline lung
function and degree of change (i.e. greater changes were
associated with higher baseline lung functions). To allow for
this paired t tests were used to compare the mean change in lung
function controlled by baseline between the two IV antibiotic
courses.
3. Results
Twenty six patients received temocillin, fourteen were male
and twelve female, with a mean (SD) age of 28 (6) years. Fifteen
patients were infected with B. cepacia complex (B. cenocepaciaFig. 1. Change in FEV1% start to end of temocillin course.
Table 3
Mean difference between temocillin and non-temocillin courses (values are
expressed as mean difference [95%CI])
Difference between temocillin and non-temocillin courses
Group FEV1% predicted FVC% predicted
Whole group 0.46% [−4.55 to 5.48] 1.81% [−4.59 to 8.20]
Bcc group 1.06% [−5.82 to 7.94] 2.13% [−6.78 to 11.03]
Pa group −0.5% [−9.22 to 8.22] 1.3% [−9.55 to 12.15]
Bcc group: patients infected by B. cenocepacia; Pa group: patients infected by
P. aeruginosa, Whole group: Bcc+Pa.
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phylococcus aureus was also present in three patients
(B. cenocepacia n=1, P. aeruginosa n=2). Sensitivity of
organisms to temocillin was tested in twelve patients; in nine
patients the organism was sensitive to temocillin (B. cenoce-
pacia n=6; P. aeruginosa n=3) and resistant in three
(B. cenocepacia n=2; P. aeruginosa n=1). Concomitant
antibiotics for temocillin and non-temocillin courses are
summarised in Table 1. Baseline lung function was comparable
and not significantly different (pN0.05) at the beginning of both
IV antibiotic courses (Table 2). Duration of infection was
14 days for the non-temocillin course and 21 days for the
temocillin course.
Improvement in FEV1% was similar for the temocillin and
non-temocillin courses (Figs. 1 and 2). Analysis of the whole
group showed the mean (SD) increase in FEV1% for the
temocillin course was 7.12 (11.67)% and for the non-temocillin
course was 6.65 (7.62)%. The mean (SD) of increase in FVC%
for the temocillin course was 8.85 (14.04)% and for the non-
temocillin course the increase was 7.04 (7.96)% (Table 2).
A mean difference in FEV1% of 0.46% [95% CI: −4.55 to
5.48%] and a mean difference in FVC% of 1.81% [95%
CI: −4.59 to 8.20] were found both in favour of temocillin.
When patients were categorized by infecting bacteria and
analysed in subgroups there was no statistically significant
difference between IV antibiotic courses for either the patients
infected with B. cepacia complex or with P. aeruginosa. In
the B. cepacia complex group the mean difference in FEV1%
was 1.06% [95%CI: −5.82 to 7.94] and the mean difference in
FVC% was 2.13% [95%CI: −6.78 to 11.03], both differences
were observed in favour of temocillin. In the patients who
isolated P. aeruginosa the mean difference in FEV1% was
0.5% [95%CI: −9.22 to 8.22] and was observed in favour of
the non-temocillin course while the mean difference in FVC%Fig. 2. Change in FEV1% start to end of non-temocillin course.was 1.3% [95% CI: −9.55 to 12.15] and observed in favour of
the temocillin course (Table 3).
4. Discussion
In this study temocillin was used primarily for the treatment
of severe lung disease as is the practice in both centres. Both IV
antibiotic courses elicited improvements in lung function and no
significant difference was observed between the temocillin
course and the non-temocillin course. The confidence intervals
for the differences are wide and may partly be explained by the
small sample size.
There are few data available about temocillin and B. cepacia
complex or P. aeruginosa activity. Although, there is evidence to
indicate that temocillin alone displays high in-vitro activity
against B. cepacia complex. Conversely, P. aeruginosa is almost
always reported resistant although synergistic effects when used
in combination with aminoglycoside antibiotics can be seen
[8,14,17,18]. Two previous retrospective studies have shown
clinical improvement with antibiotic therapy including temocillin
for respiratory exacerbations in CF associated with B. cepacia
complex [16,19]. Clinical improvement occurred in 56% of
courses in the study by Lekkas et al. (2006) and 75% of courses in
the study by Taylor et al. (1992) compared to 69% in the group
colonised with B. cepacia complex in the present study [16,19].
This study is the first to compare treatment with temocillin to
standard combination therapy, adding to the limited clinical data
on the efficacy of temocillin for treating respiratory exacerba-
tions in severe lung disease in CF. These findings need to be
investigated in a prospective study however due to the small
difference the sample needed would be large. Using data from
this study for FEV1% as the outcome measure, all patients
combined, to get a power of 90% to declare equivalence, with
an alpha of 5% and an equivalence margin of 5%, 68 patients in
each group would be needed.
The retrospective design of this study results in some
limitations. Many patients were administered IV antibiotics at
home and did not have all outcome measures recorded at the
start and end of each course. Moreover, very few patients had
CRP, neutrophil count and weight recorded preventing any
further analyses. The longer duration of the temocillin course
indicates that at this stage patients were sicker and despite this
there was no difference in treatment effects between courses.
Finally, as temocillin was given in conjunction with an
aminoglycoside it is impossible to assess the individual effects
554 L. Kent et al. / Journal of Cystic Fibrosis 7 (2008) 551–554of each antibiotic. However, aminoglycosides have been
administered to all patients in both courses which decreases in
part the influence of this second antimicrobial, and allows for
comparison between temocillin and the other treatment, as each
patient becomes their own control.
In conclusion these results support previous reports that the
efficacy of temocillin is equivalent for B. cepacia complex
when compared to standard combination therapy for an acute
exacerbation of respiratory disease due to multi-resistant
bacteria in CF [16,19].
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